Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses

Laura T. Letendre Merial Ltd, 3239 Satellite Blvd, Duluth, GA 30096

Search for other papers by Laura T. Letendre in
Current site
Google Scholar
PubMed
Close
 PhD
,
Ronald K. Tessman Merial Ltd, 3239 Satellite Blvd, Duluth, GA 30096

Search for other papers by Ronald K. Tessman in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Scott R. McClure Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011

Search for other papers by Scott R. McClure in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Valerie J. Kvaternick Merial Ltd, 3239 Satellite Blvd, Duluth, GA 30096

Search for other papers by Valerie J. Kvaternick in
Current site
Google Scholar
PubMed
Close
 MS
,
James B. Fischer Merial Ltd, 3239 Satellite Blvd, Duluth, GA 30096

Search for other papers by James B. Fischer in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Peter D. Hanson Merial Ltd, 3239 Satellite Blvd, Duluth, GA 30096

Search for other papers by Peter D. Hanson in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To determine pharmacokinetic parameters and variables, firocoxib concentrations in urine and plasma, urine-to-plasma ratios, and the urine depletion profile of firocoxib and to evaluate whether the pharmacokinetic behavior of firocoxib was governed by linear processes after multiple doses of firocoxib were administered IV and orally.

Animals—6 healthy female horses (5 Paint horses and 1 Quarter Horse) in experiment 1 and 12 healthy male and female horses in experiment 2.

Procedures—In experiment 1, 6 horses were orally administered firocoxib paste once daily for 12 consecutive days, and plasma and urine samples were obtained and analyzed. In a second experiment, 12 horses received IV injections of firocoxib solution once daily for 9 consecutive days, and plasma was obtained and analyzed.

Results—Mean ± SD clearance and steady-state volume of distribution of firocoxib were 40.5 ± 14.7 mL/h/kg and 2.3 ± 0.7 L/kg, respectively. Mean half-life was 44.2 ± 21.6 hours and 36.5 ± 9.5 hours for IV and oral administration, respectively. The urine concentration– time curve decreased in parallel with the plasma concentration-verus-time curve. Renal clearance (0.26 ± 0.09 mL/kg/h) was low, compared with total body clearance, which indicated that the main route of elimination was hepatic clearance.

Conclusions and Clinical Relevance—The pharmacokinetics of firocoxib during prolonged use were determined. Use of plasma or urine to ascertain drug concentrations in horses is scientifically valid because the plasma-to-urine ratio was consistent over time and among horses.

Abstract

Objective—To determine pharmacokinetic parameters and variables, firocoxib concentrations in urine and plasma, urine-to-plasma ratios, and the urine depletion profile of firocoxib and to evaluate whether the pharmacokinetic behavior of firocoxib was governed by linear processes after multiple doses of firocoxib were administered IV and orally.

Animals—6 healthy female horses (5 Paint horses and 1 Quarter Horse) in experiment 1 and 12 healthy male and female horses in experiment 2.

Procedures—In experiment 1, 6 horses were orally administered firocoxib paste once daily for 12 consecutive days, and plasma and urine samples were obtained and analyzed. In a second experiment, 12 horses received IV injections of firocoxib solution once daily for 9 consecutive days, and plasma was obtained and analyzed.

Results—Mean ± SD clearance and steady-state volume of distribution of firocoxib were 40.5 ± 14.7 mL/h/kg and 2.3 ± 0.7 L/kg, respectively. Mean half-life was 44.2 ± 21.6 hours and 36.5 ± 9.5 hours for IV and oral administration, respectively. The urine concentration– time curve decreased in parallel with the plasma concentration-verus-time curve. Renal clearance (0.26 ± 0.09 mL/kg/h) was low, compared with total body clearance, which indicated that the main route of elimination was hepatic clearance.

Conclusions and Clinical Relevance—The pharmacokinetics of firocoxib during prolonged use were determined. Use of plasma or urine to ascertain drug concentrations in horses is scientifically valid because the plasma-to-urine ratio was consistent over time and among horses.

All Time Past Year Past 30 Days
Abstract Views 110 0 0
Full Text Views 3621 3296 2571
PDF Downloads 514 246 28
Advertisement